ObjectiveTo explore the relation of X-ray repair cross complementing 6 (XRCC6) gene polymorphism with prognosis of postoperative chemotherapy for patients with gastric cancer. MethodsA total of 99 patients with gastric cancer who received postoperative chemotherapy regimen of oxaliplatin+tegafur for treatment were selected as the research subjects, and their genotype of XRCC6 gene at locus rs2267437 in peripheral blood was detected on admission. The survival status of patients after 36 months of chemotherapy was followed up, and patients were assigned to survival group (56 cases) or death group (43 cases). The clinicopathological data and distribution frequency of genotype of XRCC6 gene were compared between patients of the two groups. The relation of XRCC6 gene polymorphism with prognosis of postoperative chemotherapy for patients with gastric cancer was analyzed by using the COX regression model. ResultsThe death group exhibited higher proportions of patients with tumor diameter＞5 cm, tumor clinical stage in Ⅲ stage, presence of lymph node metastasis, and presence of distant metastasis (all P＜0.05). There was statistically significant difference in genotype distribution frequency of XRCC6 gene between patients of the two groups (P＜0.05), therein patients in the death group obtained a lower frequency of CG genotype and GG genotype of XRCC6 gene as compared with the survival group. The results of COX regression analysis revealed that after correcting for relevant clinicopathological features, gastric cancer patients undergoing postoperative chemotherapy who carried CG/GG genotype of XRCC6 gene obtained a superior prognosis (P＜0.05). ConclusionXRCC6 gene polymorphism is closely related to prognosis of postoperative chemotherapy for patients with gastric cancer. Patients carrying CG/GG genotype have a superior prognosis.【

无